<DOC>
	<DOC>NCT00549679</DOC>
	<brief_summary>This study will evaluate the safety and tolerability of the cfor the first time in mild to moderate COPD patients.</brief_summary>
	<brief_title>Study To Evaluate Safety And Tolerability Of GSK256066 In Chronic Obstructive Pulmonary Disease (COPD) Patients</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>6-((3-((dimethylamino)carbonyl)phenyl)sulfonyl)-8-methyl-4-((3-methyloxyphenyl)amino)-3-quinolinecarboxamide</mesh_term>
	<criteria>Male adults or female adults of nonchildbearing potential who are between 40 and 75 years of age (inclusive). Subjects with a clinical diagnosis of COPD in accordance with the European Respiratory Society Consensus Statement and subjects categorised with moderate COPD as defined by the GOLD guidelines of 2006 [GOLD, 2006] Subjects with a cigarette smoking history of ≥ 10 pack years (1 pack year = 20 cigarettes smoked per day for 1 year or the equivalent). Both current and former smokers are eligible to be enrolled. A former smoker is defined as a subject who has not smoked for ≥6 months at Visit 1. Subjects with a postbronchodilator FEV1 to FVC ratio (FEV1/FVC) &lt; 0.7 at Visit 1. Subjects will be assessed 30 (± 5) minutes after receiving salbutamol 400 μg. Subjects with a postbronchodilator FEV1 ≥ 50% and &lt; 80% of predicted normal for height, age and sex at Visit 1. Subjects will be assessed 30 (± 5) minutes after receiving salbutamol 400 μg. Subjects with a normal echocardiogram at screening, as defined by the absence of clinically significant wall motion, chamber size or valvular abnormalities The subject must be capable of giving informed consent and can comply with the study requirements and timetable. Women who are premenopausal and of childbearing potential. Subjects weighing less than 50 kilograms (kg). Subjects who are obese defined as having a body mass index (BMI) &gt; 30. Subjects with a current diagnosis of asthma. Subjects who have required hospitalisation or treatment with oral corticosteroids and/or antibiotic therapy for acute worsening of COPD or lower respiratory tract infection in the 6 weeks prior to Screening. Subjects who have received treatment with oral, intravenous, topical or intraarticular corticosteroids within 6 weeks of Screening or thereafter Subjects with active tuberculosis, sarcoidosis or clinically overt bronchiectasis. Subjects with a history of any type of malignancy with the exception of successfully treated squamous cell cancer of the skin. Subjects with rheumatoid arthritis, connective tissue disorders and other conditions known to be associated with chronic inflammation (e.g. Inflammatory Bowel Disease). Subjects with chronic infections (lasting longer than 6 months) such as gingivitis, periodontitis, prostatitis, gastritis, and urinary tract infections. Subjects with any acute infection, sinus symptoms, or significant trauma (burns, fractures). Subjects with clinically significant renal disease, diabetes mellitus/metabolic syndrome, hypertension or any other clinically significant cardiovascular, neurological, endocrine, or haematological abnormalities that are uncontrolled on permitted therapy. Subjects who have participated in any GSK study/studies involving administration of COA. The subject has a screening ECG parameters outside of ranges specified in protocol. Subjects with hypoxaemia Risk factors for human immunodeficiency virus (HIV), Hepatitis B or Hepatitis C infection at Screening (Visit 1). Subjects who have undergone surgery including lung volume reduction surgery in the last six months or have conditions that prevent them from performing spirometry. Subjects with a history (or suspected history) of alcohol misuse or any other recreational substance abuse. Subjects who require treatment with any of the following from the start of the runin period (Day 14) until the end of the treatment phase: Inhaled corticosteroids Inhaled cromolyn sodium or nedocromil Xanthines (theophylline preparations). Leukotriene modifiers Tiotropium Longacting inhaled beta2agonists (salmeterol, formoterol) Oral beta2agonists Subjects who are unable to abstain from other courses of medication during the run in phase including nonsteroidal antiinflammatory drugs (NSAIDs), antidepressant drugs, antihistamines, antirhinitis or hay fever medication, other than short acting inhaled betaagonists, ipratropium bromide and paracetamol (up to 4 g per day) for the treatment of minor ailments (eg headache) from 48h before the first dose until the followup visit. Subjects requiring medication between dosing and follow up may be excluded at the principal investigators discretion. Subjects with any known hypersensitivity to salbutamol or ipratropium bromide. Subjects who are participating or plan to participate in the active phase of a pulmonary rehabilitation programme during the study. Subjects who have received an investigational drug within 30 days or within five drug halflives of the investigational drug (whichever is longer). Subjects with any clinically relevant abnormality detected by the assessments at Screening. Subjects who have experienced an exacerbation during the runin period requiring treatment with oral corticosteroids and/or macrolide antibiotics and/or hospitalisation.</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Chronic Obstructive Pulmonary Disease (COPD)</keyword>
	<keyword>COPD</keyword>
	<keyword>Repeat Dose</keyword>
	<keyword>GSK256066</keyword>
</DOC>